London Stock Exchange welcomes BiVictriX Therapeutics plc

London Stock Exchange today welcomes BiVictriX Therapeutics plc (“BiVictriX”), a rapidly emerging drug discovery and development company that begins trading on AIM under the ticker symbol BVX, following a successful initial public offering.

BiVictriX has successfully raised gross proceeds of £7.5 million by way of a placing and subscription at a market capitalisation of approximately £13.2 million. The funds will enable BiVictriX to accelerate its growth strategy and expedite the development and delivery of its next-generation, highly selective cancer therapeutics.

Founded by Tiffany Thorn in 2017, BiVictriX is applying a novel approach, derived from frontline clinical experience from within the NHS, to create safer, more effective cancer therapeutics. BiVictriX has developed a proprietary platform and the resulting Bi-Cygni® therapeutics are uniquely selective for the specific cancers, potentially enabling higher dosing and more aggressive tumour eradication, while reducing life-threatening treatment-related side effects.

Tiffany Thorn, Founder and CEO of BiVictriX, said: “Today’s listing on London’s AIM is a major milestone for BiVictriX. Our vision is to revolutionise cancer therapy for the most difficult to treat cancers, making curative treatments available to all. The funds raised will help us to accelerate our growth strategy and expedite the development and delivery of our pioneering, highly selective cancer therapeutics to patients diagnosed with some of the most challenging cancers. Supporting patients who are currently in urgent need of more effective medicines.

“I would like to take this opportunity to offer our sincere gratitude and thanks to all of our staff, advisers and shareholders who have been instrumental in getting us to where we are today. I would also like to take this opportunity to welcome new shareholders to the register and thank them for their support in enabling us to continue to carry out this critical work. I look forward to life as a public company and progressing our development programmes to the next stage with the support of our shareholders.”

Advisers to the IPO include:

  • SP Angel Corporate Finance LLP – Nominated Adviser and Broker
  • Acceleris Capital Limited – Financial Adviser
  • Slater Heelis Limited – Solicitors to BiVictriX
  • Gowlings WLG (UK) LLP – Solicitors to SP Angel
  • Crowe U.K. LLP – Reporting Accountant and Auditor
  • Consilium Strategic Communications – Financial Public Relations Adviser

Quick facts

Track
Market: AIM
Instrument market cap (£m)
13.22
Listing/Admission to trading
11 Aug 2021
Looking for new and recent issues?

More recent

London International Shipping Week 2021

London International Shipping Week 2021 (LISW21) is seen throughout the world as the ‘must attend’ international maritime event of the year. London is the historic centre of global trade and world shipping and stands at the heart of international commerce. Its long-standing maritime institutions have been servicing the global shipping industry for centuries and that role co

Learn more
57.28
London Stock Exchange welcomes LungLife AI

London Stock Exchange welcomes LungLife AI, Inc. to trading on AIM. In July 2021 LungLife successfully raised gross proceeds of £17 million and the Company’s market capitalisation on admission was £45 million with a free float of 50.6%. 

LungLife AI’s mission is to make a significant impact in the early detection of lung cancer. The Company is a develop

Learn more
33.56
London Stock Exchange welcomes Likewise Group plc to AIM

Likewise is a UK distributor of both domestic and commercial floorcoverings and matting. It is challenging the established competitors in the industry by providing access to a wide choice of flooring from multiple manufacturers across the globe at competitive prices for its customers. The Directors believe they have an opportunity to build a

Learn more
144.88
London Stock Exchange welcomes BiVictriX Therapeutics plc

London Stock Exchange today welcomes BiVictriX Therapeutics plc (“BiVictriX”), a rapidly emerging drug discovery and development company that begins trading on AIM under the ticker symbol BVX, following a successful initial public offering.

BiVictriX has successfully raised gross proceeds of £

Learn more